drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (autologous T-cell therapy)
drug_description
Autologous adoptive T-cell therapy consisting of ex vivo expanded CD8+/CD4+ T cells specific for patient tumor neoantigen peptides; TCR recognition of neoantigen–HLA on tumor cells triggers cytotoxic killing and IFN-γ–mediated effects to boost tumor-specific immunity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Immunotherapy, Adoptive
drug_category
TCR SELECTED T CELLS
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous CD8+/CD4+ T cells are isolated and expanded ex vivo for specificity to patient tumor neoantigen peptides. After infusion, native TCRs recognize neoantigen–HLA complexes on tumor cells, triggering perforin/granzyme-mediated cytotoxicity and IFN-γ–driven immune activation to enhance tumor-specific immunity.
drug_name
Neoantigen Reactive T cells (NRTs)
nct_id_drug_ref
NCT06432075